Bulk Manufacturer of Controlled Substances Application: S & B PHARMA, INC., 38564 [2014-15888]
Download as PDF
<![CDATA[
38564
Federal Register / Vol. 79, No. 130 / Tuesday, July 8, 2014 / Notices
also be submitted electronically to
jtrelease@osmre.gov.
To
request a copy of the information
collection request contact John Trelease
at (202) 208–2783 or via email at
jtrelease@osmre.gov.
SUPPLEMENTARY INFORMATION: OMB
regulations at 5 CFR 1320, which
implement provisions of the Paperwork
Reduction Act of 1995 (Pub. L. 104–13),
require that interested members of the
public and affected agencies have an
opportunity to comment on information
collection and recordkeeping activities
[see 5 CFR 1320.8(d)]. This notice
identifies an information collection that
OSMRE will be submitting to OMB for
extension. This collection is contained
in 30 CFR Part 870—Abandoned Mine
Reclamation Fund—Fee Collection and
Coal Production Reporting, and the
implementing form OSM–1—Coal
Reclamation Fee Report. OSMRE will
request a 3-year term of approval for this
information collection activity.
An agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a currently valid OMB
control number. The OMB control
number for this collection is 1029–0063.
Responses are mandatory.
Comments are invited on: (1) The
need for the collection of information
for the performance of the functions of
the agency; (2) the accuracy of the
agency’s burden estimates; (3) ways to
enhance the quality, utility and clarity
of the information collection; and (4)
ways to minimize the information
collection burden on respondents, such
as use of automated means of collection
of the information. A summary of the
public comments will be included in
OSMRE’s submission of the information
collection request to OMB.
Before including your address, phone
number, email address, or other
personal identifying information in your
comment, you should be aware that
your entire comment—including your
personal identifying information—may
be made publicly available at any time.
While you can ask us in your comment
to withhold your personal identifying
information from public review, we
cannot guarantee that we will be able to
do so.
Title: 30 CFR Part 870—Abandoned
Mine Reclamation Fund—Fee
Collection and Coal Production
Reporting.
OMB Control Number: 1029–0063.
Summary: The information is used to
maintain a record of coal produced for
sale, transfer, or use nationwide each
calendar quarter, the method of coal
tkelley on DSK3SPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Mar<15>2010
16:48 Jul 07, 2014
Jkt 232001
removal and the type of coal, and the
basis for coal tonnage reporting in
compliance with 30 CFR Part 870 and
section 401 of Public Law 95–87.
Individual reclamation fee payment
liability is based on this information.
Without the collection of information
OSMRE could not implement its
regulatory responsibilities and collect
the fee.
Bureau Form Number: OSM–1.
Frequency of Collection: Quarterly.
Description of Respondents: Coal
mine permittees.
Total Annual Responses: 8,792.
Total Annual Burden Hours: 810.
Dated: July 2, 2014.
John A. Trelease,
Acting Chief, Division of Regulatory Support.
In accordance with 21 CFR
1301.33(a), this is notice that on
December 10, 2013, S & B Pharma, Inc.,
DBA Norac Pharma, 405 South Motor
Avenue, Azusa, California 91702–3232,
applied to be registered as a bulk
manufacturer of the following basic
classes of narcotic or nonnarcotic
controlled substances:
Controlled substance
Gamma Hydroxybutyric (2010) ....
Tetrahydrocannabinols (7370) .....
Methamphetamine (1105) ............
Pentobarbital (2270) .....................
Nabilone (7379) ............................
4-Anilino-N-phenethyl-4-piperidine
(8333).
Tapentadol (9780) ........................
Fentanyl (9801) ............................
Schedule
I
I
II
II
II
II
II
II
[FR Doc. 2014–15928 Filed 7–7–14; 8:45 am]
The company plans to manufacture
the listed controlled substances in bulk
for use in product development and for
commercial sales to its customers.
BILLING CODE 4310–05–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: S & B
PHARMA, INC.
ACTION:
Registered bulk manufacturers of
the affected basic classes and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.33(a) on or before
September 8, 2014.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, and
dispensers of controlled substances
(other than final orders in connection
with suspension, denial, or revocation
of registration) has been redelegated to
the Deputy Assistant Administrator of
the DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to sec. 7(g) of 28 CFR pt. 0,
subpt. R, App.
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
[FR Doc. 2014–15888 Filed 7–7–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Notice of application.
SUPPLEMENTARY INFORMATION:
Dated: July 1, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Powered
Platforms for Building Maintenance
Standard
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the Occupational
Safety and Health Administration
(OSHA) sponsored information
collection request (ICR) titled, ‘‘Powered
Platforms for Building Maintenance
Standard,’’ to the Office of Management
and Budget (OMB) for review and
approval for continued use, without
change, in accordance with the
Paperwork Reduction Act of 1995
(PRA), 44 U.S.C. 3501 et seq. Public
comments on the ICR are invited.
DATES: The OMB will consider all
written comments that agency receives
on or before August 7, 2014.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained free of charge from the
RegInfo.gov Web site at https://
www.reginfo.gov/public/do/
SUMMARY:
E:\FR\FM\08JYN1.SGM
08JYN1
]]>Agencies
[Federal Register Volume 79, Number 130 (Tuesday, July 8, 2014)]
[Notices]
[Page 38564]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-15888]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: S & B
PHARMA, INC.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before September 8, 2014.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, and dispensers of controlled substances
(other than final orders in connection with suspension, denial, or
revocation of registration) has been redelegated to the Deputy
Assistant Administrator of the DEA Office of Diversion Control
(``Deputy Assistant Administrator'') pursuant to sec. 7(g) of 28 CFR
pt. 0, subpt. R, App.
In accordance with 21 CFR 1301.33(a), this is notice that on
December 10, 2013, S & B Pharma, Inc., DBA Norac Pharma, 405 South
Motor Avenue, Azusa, California 91702-3232, applied to be registered as
a bulk manufacturer of the following basic classes of narcotic or
nonnarcotic controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric (2010)................ I
Tetrahydrocannabinols (7370)............... I
Methamphetamine (1105)..................... II
Pentobarbital (2270)....................... II
Nabilone (7379)............................ II
4-Anilino-N-phenethyl-4-piperidine (8333).. II
Tapentadol (9780).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for use in product development and for commercial sales to its
customers.
Dated: July 1, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-15888 Filed 7-7-14; 8:45 am]
BILLING CODE 4410-09-P
